Scottish Renal Registry, Cirrus House, Marchburn Drive, Paisley PA32SJ, UK.
QJM. 2012 Nov;105(11):1097-103. doi: 10.1093/qjmed/hcs143. Epub 2012 Aug 20.
Central venous catheters (CVC) are a potential source of bacteraemia and have been associated with increased mortality in haemodialysis patients. We aimed to investigate the relationships between haemodialysis vascular access, taking into account changes in vascular access type during patients' lives, and cause specific mortality risk in a national cohort of dialysis patients.
Prospective cohort study including all patients receiving haemodialysis in Scotland at annual cross sectional surveys in 2009, 2010 and 2011. Data were collected through the Scottish Renal Registry and by a structured review of case records following death. Cox proportional hazards regression and multivariable logistic regression were used to model survival and risk of death from septicaemia respectively.
Of a cohort of 2666 patients, 873 (32%) died during follow-up. After case-mix adjustment, patients using only tunnelled CVC during follow-up had a higher risk of all cause mortality across all strata of prior renal replacement therapy exposure [adjusted hazard ratio (HR): 1.83-2.08]. Case-mix adjusted risks of cardiovascular death (adjusted HR: 2.20-2.95) and infection-related death (adjusted HR: 3.10-3.63) were also higher in this group. Patients using tunnelled CVCs during follow-up and prior to death had 6.9-fold higher odds of death from septicaemia compared with those using only arteriovenous fistulae or grafts.
Compared with an arteriovenous fistula or graft, sustained use of tunnelled CVCs for vascular access is associated with higher risks of all-cause, cardiovascular and infection-related mortality.
中心静脉导管(CVC)是菌血症的潜在来源,并与血液透析患者的死亡率增加有关。我们旨在调查血液透析血管通路之间的关系,同时考虑到患者一生中血管通路类型的变化,以及在全国范围内的透析患者队列中特定病因死亡率的风险。
这是一项前瞻性队列研究,纳入了 2009 年、2010 年和 2011 年年度横断面调查中在苏格兰接受血液透析的所有患者。数据通过苏格兰肾脏登记处收集,并通过对死亡后病例记录的结构化审查收集。使用 Cox 比例风险回归和多变量逻辑回归分别对生存和败血症死亡风险进行建模。
在 2666 名患者的队列中,873 名(32%)在随访期间死亡。在病例混合调整后,仅在随访期间使用隧道式 CVC 的患者在所有先前肾脏替代治疗暴露分层中全因死亡率的风险更高[调整后的危险比(HR):1.83-2.08]。在该组中,心血管死亡(调整后的 HR:2.20-2.95)和感染相关死亡(调整后的 HR:3.10-3.63)的风险也更高。在随访期间和死亡前使用隧道式 CVC 的患者因败血症死亡的可能性比仅使用动静脉瘘或移植物的患者高 6.9 倍。
与动静脉瘘或移植物相比,持续使用隧道式 CVC 进行血管通路与全因、心血管和感染相关死亡率的风险增加相关。